Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord blood regulatory T cells + liraglutide
- Development stage
- Unknown
- Lead developer
- The Second Xiangya Hospital
- Modality
- Cell Therapies, Peptides
- Administration
- Intravenous, Subcutaneous
01
Overview
This investigational combination therapy consists of ex-vivo expanded umbilical cord blood-derived regulatory T cells (UCB-Tregs) and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Developed by the Second Xiangya Hospital of Central South University, the treatment is designed to address the underlying autoimmune pathology of Type 1 Diabetes Mellitus (T1D) and Latent Autoimmune Diabetes in Adults (LADA). The UCB-Tregs are intended to reconstitute immune tolerance and protect pancreatic beta cells from autoimmune destruction by suppressing effector T-cell responses. Liraglutide is included to provide additional metabolic benefits, improve glycemic control, and potentially promote beta-cell preservation. The therapy is currently being evaluated in a Phase 1/2 clinical trial (NCT03011021) in China.
- Other names
- UCB-Treg and LiraglutideEx-vivo expanded umbilical cord blood regulatory T cellsUCB-Tregs
02
Targets
GLP1R (GLP-1R)pMHC–TCR (Peptide–MHC–T-cell receptor complex)
Beyond the preview
Go deeper on umbilical cord blood regulatory T cells + liraglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord blood regulatory T cells + liraglutide.